admin

Agreement enables the development of therapeutics, including AcuraStem’s AS-202
Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase.

MONROVIA, Calif., Sept. 25, 2023 — AcuraStem, a patient-based biotechnology
company pioneering how treatments are developed for neurodegenerative diseases,
announced today that it has entered into a license agreement with Takeda to develop
and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an
innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral
Sclerosis (ALS).

[Read more…] about AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

Freienbach, September 19 , 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement with Radius Health, Inc for Binosto® for the United States. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO® provides an important once-weekly treatment option, particularly for patients with osteoporosis who may not be able to take alendronate tablets. Radius is a major player in the U.S. bone market and currently markets TYMLOS® for the treatment of osteoporosis in the U.S. BINOSTO® expands Radius’ presence in the treatment of bone health with a second product for the approximately 10 million people in the U.S. living with osteoporosis.

[Read more…] about EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States